Principal Financial Group Inc. Has $9.70 Million Position in DaVita Inc. (NYSE:DVA)

Principal Financial Group Inc. trimmed its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 5.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,168 shares of the company's stock after selling 3,647 shares during the period. Principal Financial Group Inc. owned approximately 0.07% of DaVita worth $9,699,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Bessemer Group Inc. grew its position in shares of DaVita by 2,335.6% during the 1st quarter. Bessemer Group Inc. now owns 10,741 shares of the company's stock worth $1,483,000 after buying an additional 10,300 shares in the last quarter. Sei Investments Co. grew its position in shares of DaVita by 21.3% during the 1st quarter. Sei Investments Co. now owns 41,952 shares of the company's stock worth $5,790,000 after buying an additional 7,371 shares in the last quarter. BOKF NA grew its position in shares of DaVita by 286,550.0% during the 1st quarter. BOKF NA now owns 5,733 shares of the company's stock worth $790,000 after buying an additional 5,731 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of DaVita by 29.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company's stock worth $6,942,000 after buying an additional 11,454 shares in the last quarter. Finally, Comerica Bank boosted its position in DaVita by 41.4% during the first quarter. Comerica Bank now owns 34,431 shares of the company's stock valued at $4,753,000 after purchasing an additional 10,074 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on DVA shares. Truist Financial increased their price target on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. Barclays raised their price objective on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. TD Cowen lifted their price target on DaVita from $139.00 to $150.00 and gave the company a "hold" rating in a research report on Wednesday, July 24th. UBS Group raised their price objective on DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a report on Thursday, August 8th. Finally, Bank of America raised their price objective on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $161.80.

Insider Buying and Selling

In other news, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the completion of the sale, the chief executive officer now owns 905,659 shares in the company, valued at approximately $141,219,407.87. This represents a 3.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the sale, the chief financial officer now owns 111,481 shares of the company's stock, valued at $17,286,243.86. The trade was a 36.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 156,086 shares of company stock valued at $24,807,161 in the last three months. 2.00% of the stock is currently owned by corporate insiders.

DaVita Price Performance

DaVita stock traded up $0.22 during mid-day trading on Tuesday, hitting $157.63. 312,288 shares of the company were exchanged, compared to its average volume of 819,530. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The business's 50 day simple moving average is $157.92 and its two-hundred day simple moving average is $147.72. The company has a market capitalization of $12.93 billion, a P/E ratio of 17.07, a PEG ratio of 0.90 and a beta of 0.89. DaVita Inc. has a 12-month low of $95.60 and a 12-month high of $168.50.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion during the quarter, compared to analysts' expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. DaVita's revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.85 EPS. Analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.